S-1 · primary offering
Issued 2024
Proposed maximum
Shares registered
- Filed
- Effective
PCSA$1.89+2.16%
Processa Pharmaceuticals, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$5.28M
Float & O/S:
Inst Own:
DilutionScan read 54 of Processa Pharmaceuticals, Inc.'s SEC filings and found 10 warrant series, 2 convertibles, 1 ATM program, 2 shelf registrations, 2 S-1 registrations and 5 completed offerings on file for PCSA. The latest dilution event on file is a registration statement on Oct 23, 2026. Analysis updated Oct 29, 2026.
Signal8 Summary
PCSA
Distressed biotech with exhausted cash
Snapshot
Processa is a clinical-stage biotech with zero revenue and severe financial strain. It burned $11.4M in free cash flow against only $5.5M in cash, resulting in a negative cash runway. The company recently executed a 1-for-25 reverse split and massively diluted shareholders, increasing the share count by nearly 970% in one year. Despite this, nine insiders, including the CEO and CFO, have collectively purchased about $163K of stock in the last 90 days, a significant bet for a company of this size.
Ownership
Institutions hold 4.7% and insiders hold 3.1%.
Raise routes on file: active ATM + effective shelf · latest dilution event 11 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
Oct 23, 2026 · Registration
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Completed
S-1 · primary offering
Issued 2025
Proposed maximum
Shares registered
- Filed
- Effective
Series A Warrants (January 2025 Offering)
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Series B Warrants (January 2025 Offering)
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Common Warrants (June 2025 Offering)
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Placement Agent Warrants (June 2025 Offering)
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Common Warrants (January 2024 Offering)
Issued 2024
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Series A Non-Voting Convertible Preferred Stock — 2026 Private Placement (PIPE)
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
ATM program
Issued 2024
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
S-3 shelf registration
Issued 2024
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2026
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
PIPE
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
PIPE
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
PIPE
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
ATM block sale
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
PIPE
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Know who's about to sell into your PCSA trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
